​

PTC Therapeutics (PTCT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PTCT Stock Forecast

PTC Therapeutics (PTCT) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $87.86, with a high of $120.00 and a low of $50.00. This represents a 28.09% increase from the last price of $68.59.

$25 $44 $63 $82 $101 $120 High: $120 Avg: $87.86 Low: $50 Last Closed Price: $68.59

PTCT Stock Rating

PTC Therapeutics stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (57.69%), 9 Hold (34.62%), 2 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 26 0 2 9 15 Strong Sell Sell Hold Buy Strong Buy

PTCT Price Target Upside V Benchmarks

TypeNameUpside
StockPTC Therapeutics28.09%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1614
Avg Price Target$108.00$101.17$86.57
Last Closing Price$68.59$68.59$68.59
Upside/Downside57.46%47.50%26.21%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 263551-14
Mar, 263641-14
Feb, 263741-15
Jan, 262751-15
Dec, 252751-15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 10, 2026Tiago FauthRaymond James$108.00$69.1156.27%57.46%
Feb 23, 2026Morgan Stanley$92.00$70.6630.20%34.13%
Feb 23, 2026Eliana MerleBarclays$120.00$70.6669.83%74.95%
Feb 20, 2026Brian AbrahamsRBC Capital$82.00$67.9520.68%19.55%
Feb 20, 2026Wells Fargo$86.00$69.9023.03%25.38%
Jan 27, 2026Barclays$119.00$75.4957.64%73.49%
Jan 08, 2026Morgan Stanley$90.00$77.2416.52%31.21%
Dec 01, 2025RBC Capital$91.00$85.995.83%32.67%
Nov 05, 2025Goldman Sachs$50.00$71.79-30.35%-27.10%
Nov 05, 2025Tiago FauthWells Fargo$93.00$67.7237.33%35.59%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 10, 2026Raymond JamesMarket PerformOutperforminitialise
Feb 23, 2026Morgan StanleyOverweightOverweighthold
Feb 23, 2026BarclaysOverweightOverweighthold
Feb 20, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 20, 2026RBC CapitalSector PerformSector Performhold
Jan 29, 2026Cowen & Co.HoldHoldhold
Jan 27, 2026BarclaysEqual-WeightOverweightupgrade
Jan 08, 2026Morgan StanleyOverweightOverweighthold
Dec 01, 2025RBC CapitalOutperformSector Performdowngrade
Nov 05, 2025Cowen & Co.HoldHoldhold

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.43$-7.79$-8.37$-4.73$8.58---
Avg Forecast$-6.68$-6.96$-7.09$-4.52$-1.40$-1.63$-0.53$0.32
High Forecast$-5.48$-4.15$-5.97$-3.20$-0.57$1.00$1.54$0.62
Low Forecast$-7.72$-14.90$-9.02$-5.17$-2.36$-6.27$-3.09$0.22
Surprise %11.23%11.93%18.05%4.65%-712.86%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$538.59M$698.80M$937.82M$806.78M$1.73B---
Avg Forecast$524.98M$716.43M$943.98M$797.55M$726.66M$884.80M$1.09B$1.16B
High Forecast$587.90M$1.35B$945.10M$797.70M$778.11M$897.16M$1.12B$1.98B
Low Forecast$452.26M$494.03M$942.01M$797.40M$675.21M$872.44M$1.05B$879.21M
Surprise %2.59%-2.46%-0.65%1.16%138.16%---

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-523.90M$-559.02M$-626.60M$-363.30M$682.64M---
Avg Forecast$-436.99M$-398.38M$-626.60M$-313.22M$-46.36M$-145.50M$-63.54M$23.91M
High Forecast$-349.59M$-318.70M$-501.28M$-239.54M$-42.57M$74.52M$115.61M$46.13M
Low Forecast$-524.39M$-478.05M$-751.92M$-386.90M$-176.78M$-469.44M$-231.58M$16.44M
Surprise %19.89%40.32%-15.99%-1572.56%---

PTCT Forecast FAQ

Is PTC Therapeutics stock a buy?

PTC Therapeutics stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 9 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that PTC Therapeutics is a favorable investment for most analysts.

What is PTC Therapeutics's price target?

PTC Therapeutics's price target, set by 26 Wall Street analysts, averages $87.86 over the next 12 months. The price target range spans from $50 at the low end to $120 at the high end, suggesting a potential 28.09% change from the previous closing price of $68.59.

How does PTC Therapeutics stock forecast compare to its benchmarks?

PTC Therapeutics's stock forecast shows a 28.09% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for PTC Therapeutics over the past three months?

  • April 2026: 21.43% Strong Buy, 35.71% Buy, 35.71% Hold, 7.14% Sell, 0% Strong Sell.
  • March 2026: 21.43% Strong Buy, 42.86% Buy, 28.57% Hold, 7.14% Sell, 0% Strong Sell.
  • February 2026: 20.00% Strong Buy, 46.67% Buy, 26.67% Hold, 6.67% Sell, 0% Strong Sell.

What is PTC Therapeutics’s EPS forecast?

PTC Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.63, marking a -119.00% decrease from the reported $8.58 in 2025. Estimates for the following years are $-0.53 in 2027, and $0.32 in 2028.

What is PTC Therapeutics’s revenue forecast?

PTC Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $884.8M, reflecting a -48.87% decrease from the reported $1.73B in 2025. The forecast for 2027 is $1.09B, and $1.16B for 2028.

What is PTC Therapeutics’s net income forecast?

PTC Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-145M, representing a -121.31% decrease from the reported $682.64M in 2025. Projections indicate $-63.541M in 2027, and $23.91M in 2028.